DOCSLIB.ORG

DRAFT April 2005

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
DRAFT April 2005 1 DRAFT for review - do not cite or quote 2 3 4 5 6 7 IPCS EVALUATION OF ANTIDOTES 8 9 IN POISONING BY METALS AND METALLOIDS 10 11 12 13 14 15 16 17 Succimer 18 (2,3-Dimercaptosuccinic acid, DMSA) 19 20 21 22 23 24 25 26 27 First Draft: Professor Ole Anderson, dr.med., 28 Department of Life Sciences and Chemistry, Roskilde University, 29 Denmark 30 31 32 33 Revision, November 2005: Nicola Bates MSc, MA, Medical Toxicology Unit, Guy's & 34 St Thomas' NHS Foundation Trust, London, UK 35 . 36 Units corrected Feb 07, updated March 2009 37 1 38 39 40 1. INTRODUCTION 5 41 2. NAME AND CHEMICAL FORMULA 5 42 3. PHYSICO-CHEMICAL PROPERTIES 6 43 4. PHARMACEUTICAL FORMULATION AND SYNTHESIS 7 44 4.1 Routes of synthesis 7 45 4.2 Presentation and formulation 7 46 5. ANALYTICAL METHODS 7 47 5.1 Quality control procedures for the antidote 7 48 5.2 Methods for identification of the antidote 8 49 5.3. Methods for analysis of the antidote in biological samples 8 50 5.4 Analysis of the toxic agent in biological samples 8 51 6. SHELF-LIFE 8 52 7. GENERAL PROPERTIES 8 53 8. ANIMAL STUDIES 9 54 8.1 Pharmacodynamics 10 55 8.1.1 Aluminium 10 56 8.1.2 Antimony 10 57 8.1.3 Arsenic 10 58 8.1.4 Beryllium 13 59 8.1.5 Bismuth 14 60 8.1.6 Cadmium 14 61 8.1.7 Chromium 17 62 8.1.8 Cobalt 18 63 8.1.9 Copper 18 64 8.1.10 Gold 19 65 8.1.11 Lead 19 66 8.1.11.1 Effect of succimer on gastrointestinal lead absorption 23 67 8.1.11.2 Effect of succimer on brain lead concentrations 24 68 8.1.11.3 Effect of succimer on lead-induced neurotoxicity 24 69 8.1.12 Manganese 25 70 8.1.13 Mercury 25 71 8.1.14 Nickel 29 72 8.1.15 Palladium 29 73 8.1.16 Platinum 30 74 8.1.17 Polonium 30 75 8.1.18 Promethium 31 76 8.1.19 Selenium 31 2 77 8.1.20 Silver 31 78 8.1.21 Strontium 32 79 8.1.22 Thallium 32 80 8.1.23 Tin 32 81 8.1.24 Vanadium 33 82 8.1.25 Zinc 33 83 8.2 Pharmacokinetics 34 84 8.3 Toxicology 35 85 8.3.1 Acute toxicity 35 86 8.3.1.2 Subacute toxicity (28 days) 35 87 8.3.2 Chronic toxicity (180 days) 35 88 8.3.3 Reproductive toxicity and teratogenicity 35 89 8.3.4 Genotoxicity 36 90 9. VOLUNTEER STUDIES 37 91 9.1 Absorption 37 92 9.2 Distribution 37 93 9.3 Elimination 38 94 9.4 Metabolism 38 95 9.5 Effect of succimer on the excretion of metals 38 96 9.5.1 Bismuth elimination 38 97 9.5.2 Cadmium elimination 38 98 9.5.3 Lead elimination 39 99 9.5.4 Mercury elimination 39 100 9.5.5 Trace element elimination 40 101 10. CLINICAL STUDIES – CLINICAL TRIALS 41 102 10.1 Arsenic and succimer clinical trials 41 103 10.2 Copper and succimer clinical trials 41 104 10.3 Lead and succimer clinical trials 42 105 10.3.1 Study by the Treatment of Lead-Exposed Children (TLC) Study Group 45 106 10.4 Mercury and succimer clinical trials 46 107 11 CASE REPORTS – CLINICAL STUDIES 47 108 11.1 Aluminium 47 109 11.2 Antimony 47 110 11.3 Arsenic 48 111 11.4 Beryllium 51 112 11.5 Bismuth 52 113 11.6 Cadmium 52 114 11.7 Cobalt 52 115 11.8 Copper 52 3 116 11.8.1 Use in Wilson’s disease 52 117 11.9 Gold 52 118 11.10 Lead 53 119 11.10.1 Acute lead poisoning in children 53 120 11.10.2 Chronic lead poisoning in children 54 121 11.10.3 Chronic lead poisoning in adults 54 122 11.10.4 Chronic lead poisoning in pregnancy 56 123 11.11 Manganese 57 124 11.12 Mercury 57 125 11.13 Thallium 61 126 11.14 Tin 61 127 12. SUMMARY OF EVALUATION 61 128 12.1 Indications 61 129 12.2 Advised routes and dose 62 130 12.3 Other consequential or supportive therapy 62 131 12.4 Controversial issues and areas of insufficient information 63 132 12.5 Proposals for further studies 63 133 12.6 Adverse effects 64 134 12.7 Restrictions for use 65 135 13. MODEL INFORMATION SHEET 66 136 13.1 Use 66 137 13.2 Dosage and route 67 138 13.3 Precautions/contraindications 68 139 13.4 Pharmaceutical incompatibilities and drug interactions 68 140 13.5 Adverse effects 68 141 13.6 Use in pregnancy and lactation 68 142 13.7 Storage 69 143 14. REFERENCES 69 144 ABBREVIATIONS 90 4 145 1. INTRODUCTION 146 147 Succimer (meso-2,3-dimercaptosuccinic acid, DMSA) was orginally used to increase 148 antimony uptake during treatment for schistosomiasis, in the form of antimony a,a'- 149 dimercapto potassium succinate (Friedman et al., 1954); it was Liang et al. (1957a) 150 who first demonstrated its effectiveness as a metal-binding agent. From the mid- 151 1950s succimer was studied and used in China (Liang et al., 1957a; Wang et al., 152 1965; Li & Ding, 1989; Ding & Liang, 1991) and Russia (Petrunkin, 1956; 1959) for the 153 treament of metal poisoning. 154 155 Friedheim (1963) published an improved synthetic method in the early 1960s but the 156 wider use of succimer as a therapeutic metal-binding agent did not occur until 157 Friedheim & Corvi (1975) demonstrated the efficiency of succimer in mercury 158 poisoning in mice and guinea pigs. 159 160 Both succimer and unithiol (2,3-dimercapto-1-propanesulphonic acid, DMPS) are 161 derivatives of dimercaprol (2,3-dimercapto-1-propanol, British Anti-Lewisite, BAL), and 162 they are replacing dimercaprol as the main antidote used in the management of heavy 163 metal poisoning (Aposhian et al., 1995; Andersen, 1999). These derivatives have 164 several advantages over dimercaprol including lower toxicity, increased solubility in 165 water and lower lipid solubility. It is due to these properties that they are effective by 166 oral administration. Also, succimer decreases the brain deposition of lead (Cory- 167 Slechta, 1988) and methyl mercury (Aaseth & Friedheim, 1978). Succimer is less 168 toxic than unithiol and where these two drugs appear to have similar efficacy as an 169 antidote for a particular metal, succimer is generally preferred. 170 171 Succimer has been demonstrated to be an efficient antidote for many heavy metals 172 and metalloids, including antimony, inorganic and organic arsenic, lead, and inorganic 173 and organic mercury, and to posses some antidotal efficiency for others, such as 174 cobalt, organic tin and platinum. Its antidotal spectrum is still under investigation. 175 Also, clinical investigations of its efficiency in human metal intoxications are 176 accumulating, and the efficacy of succimer has been reported in the treatment of 177 human intoxications with lead, mercury and arsenic. Due to the high stability of the 178 succimer complexes with technetium, they are also used as scintigraphic agents, e. g. 179 in various renal disorders. 180 181 Succimer is well tolerated and adverse effects are relatively rare. The most common 182 adverse effects are mild gastrointestinal discomfort, skin reactions, and transient, 183 clinically insignificant elevated liver enzymes. Symptoms are usually mild, self-limiting 184 and do not require cessation of therapy. 185 186 Experimental and clinical uses of metal-binding agents with special emphasis on 187 succimer have previously been reviewed by Aposhian (1983), Aposhian & Aposhian 188 (1990), Ding & Liang (1991), Aposhian et al. (1992); Aposhian et al. (1995) and 189 Andersen (2004). 190 191 192 2. NAME AND CHEMICAL FORMULA 193 194 Succimer is structurally analogous to dimercaprol. It has an asymmetric carbon atom 195 and can occur in the D-, L- or meso-form. The meso-form is easier to prepare, more 5 196 readily available and used in most animal and clinical studies; it is the form available in 197 pharmaceutical preparations. 198 199 International non-proprietary name: Succimer 200 201 Synonyms: DMSA, DMS, dimercaptosuccinic acid, 2,3-dimercaptobutanedioic acid, 202 DIM-SA, meso-2,3-dithiosuccinic acid, Rol-7977 203 204 IUPAC name: 2,3-bis-sulfanylbutanedioic acid 205 206 CAS number: 304-55-2 207 208 Molecular formula: C4H6O4S2 209 210 O SH OH OH SH O 211 212 213 Relative molecular mass: 182.22 214 215 Conversion table: 1 g = 5.5 mmol 216 1 mmol = 182.2 mg 217 g/L = 5.5 mmol/L 218 mmol/L = 0.182 g/L 219 220 Manufacturer: Succimer is available in the the west as Chemet® from Sanofi-Aventis, 221 174, av. de France 75013, Paris, France and distributed by Ovation Pharmaceuticals, 222 Inc., Deerfield, Illinois, USA. It is also available from pharmaceutial manufacturers in 223 Asia (e.g. YoungCom Company Ltd, Shenzhen, China). 224 225 226 3. PHYSICO-CHEMICAL PROPERTIES 227 228 229 Physical condition: White crystalline powder with characteristic mecaptan 230 odour and taste 231 232 Melting point: 196-198oC (meso-form) 233 124-125oC (DL-form) 234 235 Boiling point: Not applicable 6 236 237 Solubility: Meso-succimer is sparingly soluble; it can be titrated with 238 alkali to pH around 5.5 or mixed in sodium bicarbonate 239 5.5% to dissolve it (Aposhian, 1983). 240 DL-succimer is readily soluble in water.
Load more

Recommended publications
  • Review of Succimer for Treatment of Lead Poisoning
    Review of Succimer for treatment of lead poisoning Glyn N Volans MD, BSc, FRCP. Department of Clinical Pharmacology, School of Medicine at Guy's, King's College & St Thomas' Hospitals, St Thomas' Hospital, London, UK Lakshman Karalliedde MB BS, DA, FRCA Consultant Medical Toxicologist, CHaPD (London), Health Protection Agency UK, Visiting Senior Lecturer, Division of Public Health Sciences, King's College Medical School, King's College , London Senior Research Collaborator, South Asian Clinical Toxicology Research Collaboration, Faculty of Medicine, Peradeniya, Sri Lanka. Heather M Wiseman BSc MSc Medical Toxicology Information Services, Guy’s and St Thomas’ NHS Foundation Trust, London SE1 9RT, UK. Contact details: Heather Wiseman Medical Toxicology Information Services Guy’s & St Thomas’ NHS Foundation Trust Mary Sheridan House Guy’s Hospital Great Maze Pond London SE1 9RT Tel 020 7188 7188 extn 51699 or 020 7188 0600 (admin office) Date 10th March 2010 succimer V 29 Nov 10.doc last saved: 29-Nov-10 11:30 Page 1 of 50 CONTENTS 1 Summary 2. Name of the focal point in WHO submitting or supporting the application 3. Name of the organization(s) consulted and/or supporting the application 4. International Nonproprietary Name (INN, generic name) of the medicine 5. Formulation proposed for inclusion 6. International availability 7. Whether listing is requested as an individual medicine or as an example of a therapeutic group 8. Public health relevance 8.1 Epidemiological information on burden of disease due to lead poisoning 8.2 Assessment of current use 8.2.1 Treatment of children with lead poisoning 8.2.2 Other indications 9.
    [Show full text]
  • Unit One Part 2: Naming and Functional Groups
    gjr-–- 1 Unit One Part 2: naming and functional groups • To write and interpret IUPAC names for small, simple molecules • Identify some common functional groups found in organic molecules O CH3 H3C N H N O N N O H3C S N O N H3C viagra™ (trade name) sildenafil (trivial name) 5-(2-ethoxy-5-(4-methylpiperazin-1-ylsulfonyl)phenyl)-1-methyl-3-propyl-1H- pyrazolo[4,3-d] pyrimidin-7(6H)-one dr gareth rowlands; [email protected]; science tower a4.12 http://www.massey.ac.nz/~gjrowlan gjr-–- 2 Systematic (IUPAC) naming PREFIX PARENT SUFFIX substituents / minor number of C principal functional functional groups AND multiple bond group index • Comprises of three main parts • Note: multiple bond index is always incorporated in parent section No. Carbons Root No. Carbons Root Multiple-bond 1 meth 6 hex Bond index 2 eth 7 hept C–C an(e) 3 prop 8 oct C=C en(e) 4 but 9 non C≡C yn(e) 5 pent 10 dec gjr-–- 3 Systematic (IUPAC) naming: functional groups Functional group Structure Suffix Prefix General form O –oic acid acid –carboxylic acid carboxy R-COOH R OH O O –oic anhydride anhydride –carboxylic anhydride R-C(O)OC(O)-R R O R O –oyl chloride acyl chloride -carbonyl chloride chlorocarbonyl R-COCl R Cl O –oate ester –carboxylate alkoxycarbonyl R-COOR R OR O –amide amide –carboxamide carbamoyl R-CONH2 R NH2 nitrile R N –nitrile cyano R-C≡N O –al aldehyde –carbaldehyde oxo R-CHO R H O ketone –one oxo R-CO-R R R alcohol R OH –ol hydroxy R-OH amine R NH2 –amine amino R-NH2 O ether R R –ether alkoxy R-O-R alkyl bromide bromo R-Br (alkyl halide) R Br (halo) (R-X) gjr-–- 4 Nomenclature rules 1.
    [Show full text]
  • Polymeric Reagents with Propane-1,3-Dithiol Functions and Their Precursors for Supported Organic Syntheses
    J. Org. Chem. 2000, 65, 4839-4842 4839 Polymeric Reagents with Propane-1,3-dithiol Functions and Their Precursors for Supported Organic Syntheses Vincenzo Bertini,*,† Francesco Lucchesini,† Marco Pocci,† and Angela De Munno‡ Dipartimento di Chimica e Tecnologie Farmaceutiche ed Alimentari, Universita´ di Genova, Via Brigata Salerno, I-16147 Genova, Italy, and Dipartimento di Chimica e Chimica Industriale, Universita´ di Pisa, Via Risorgimento, 35, I-56126 Pisa, Italy [email protected] Received January 19, 2000 Reliable completely odorless syntheses of soluble copolymeric reagents of styrene type containing propane-1,3-dithiol functions able to convert carbonyl compounds into 1,3-dithiane derivatives and to support other useful transformations are reported together with their progenitor copolymers containing benzenesulfonate or thioacetate groups perfectly stable in open air and suitable for unlimited storage. The effectiveness of the prepared reagents as tools for polymer-supported syntheses to produce ketones by aldehyde umpolung and alkylation is tested in the conversion of benzaldehyde to phenyl n-hexyl ketone starting from copolymers with different contents of active units and molecular weights. To facilitate the adaptation of the prepared soluble copolymeric reagents to other possible applications, a table of solvents and nonsolvents is presented. Introduction Scheme 1 Recently we have reported in a preliminary com- munication1 how to harness the great synthetic potenti- alities of thioacetals and thioketals by preparing, with a completely odorless synthesis, polymeric reagents2,3 of styrene type containing propane-1,3-dithiol functions effective in producing ketones by aldehyde umpolung and alkylation after the formation of 1,3-dithiane derivatives. Such polymeric reagents were obtained through a pro- cedure based on the use of the difunctional monomer 1 prepared from commercial 4-vinylbenzyl chloride (Scheme 1), its copolymerization with styrene, and chemical modification of its copolymers.
    [Show full text]
  • WIIINIPEG, I{ANI1.Oba October 1971
    THE UNTVERSITY OF FJAI,TTTOBA STTIDIES ON TSOTHTÁ.ZOIIU}.I SÂLTS AND REIATED CO},IPOUI{DS by GART ED}¡ARD BACIIERS A T}MSIS SIMÌ,1TTTED TO TI{E FACULTY OF GR]I.DUÀTE STIIDIES ÏN PIIRÎI/iL FULIi'TIJ'&Til'r OF TI# REQUTREI.Tiü{TS TÇR TI.III DEGREE I'IÂSTER 0F SCIEÎIICE DEPARTI'ÎE]VT 0F CI{EI,IISTRY WIIINIPEG, I{ANI1.oBA October 1971 üF fi "*i¡l,''ÉËR$$iY LT BRARY ACIOTOIILEDGH,ÍTÍüTS : The research degcribed in thís thesis has been undertaken at tho suggestion of Dr. D. Id. McKínnon, for v¡hose guidance, advice, æd ass*stance ï exprees r¡\y sincere appreciation" My gratitud.e ie also due the National Research CounciÌ of Canada for the scholarships provid.ed. d.uring the course of this research, and the University of }ianitoba for the provisíon of laboratory facilities. Finally, I should like to thank rny colleaguee, I'fiss Sheena Loosmore, Ivlr. Joe Buchsbriber, Iilr. Pat Ma, a¡rd. Mr. Jack Wong. Their forbearance during several unusually od.or-ous experiments was admirable. 11 TA3I,E 0F.coNTlNTS ABSTRACT.......... o.. ó..... o. ...:. r. o õ i.. o.... o.......iii INTRODUCTION Ggngial.. - - . ô. :.' ..... o. ... .. .. .. .. r. .. o. .. .... 1 fsothiazoles. o r . c o. o . ... .. o. ¡. 2 ' I s o thi azo 1 um s s i al t . c . o . c . , . , . , o . ! 4-rsothiazoline-3-thiones... o... ô........ o.... r........ 13 . 3-Isothiazoline-l-thiones....o.....,r........er........18 Thiothiophthenes and an aza arialogue.. o...... c o. o... .,.19 DISCUSSION Purpose of resgarch...... c.. o...^... r.............. o., o..2J Reaction of isothiazolium salts ç¡ittr sutf:p¡ ¡ o o.
    [Show full text]
  • WO 2014/195872 Al 11 December 2014 (11.12.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/195872 Al 11 December 2014 (11.12.2014) P O P C T (51) International Patent Classification: (74) Agents: CHOTIA, Meenakshi et al; K&S Partners | Intel A 25/12 (2006.01) A61K 8/11 (2006.01) lectual Property Attorneys, 4121/B, 6th Cross, 19A Main, A 25/34 (2006.01) A61K 8/49 (2006.01) HAL II Stage (Extension), Bangalore 560038 (IN). A01N 37/06 (2006.01) A61Q 5/00 (2006.01) (81) Designated States (unless otherwise indicated, for every A O 43/12 (2006.01) A61K 31/44 (2006.01) kind of national protection available): AE, AG, AL, AM, AO 43/40 (2006.01) A61Q 19/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A01N 57/12 (2006.01) A61K 9/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, AOm 59/16 (2006.01) A61K 31/496 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/IB20 14/06 1925 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 3 June 2014 (03.06.2014) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Chelating Drug Therapy: an Update
    Open Access Austin Journal of Genetics and Genomic Research Review Article Chelating Drug Therapy: An Update Vijay Kumar1, Ashok Kumar2*, Sandeep Kumar Singh1, Manoj Kumar3, Surendra Kumar2, Dinesh Abstract 4 5 Kumar and Ragni Singh Purpose: To study the clinical effects of metal toxicity and current 1Department of Neurology, SGPGIMS, India recommendations for management, including chelation therapy, are reviewed. 2Department of Medical Genetics, SGPGIMS, India 3Department of Microbiology, SGPGIMS, India Summary: Metals are essential to many biological processes, but excess 4Department of Chemistry, Dr. R.M.L. Avadh University, of it becomes hazardous to life. These are necessary for cell growth, electron India transport chain, several enzymatic activities and response of immune systems. 5Bheem Rao Ambedkar Bihar University, India They also serve as a cofactor for several enzymes. Chelation therapy is used for clinical management of the excess of metal. However, each metal requires *Corresponding author: Ashok Kumar, Department a specific chelation agent. A chelate is a compound form between metal and a of Medical Genetics, Sanjay Gandhi Post Graduate compound that contains two or more potential ligands. A promising Fe chelator Institute of Medical Sciences, Lucknow, India is Desferrioxamine (Desferal). Penicillamine and Trientine are uses for copper Received: March 12, 2015; Accepted: April 24, 2015; chelation. Meso-2,3-Dimercaptosuccinic Acid (DMSA) and 2,3-Dimercapto- Published: April 27, 2015 Propanesulphonate (DMPS) can be used as effective chelator of mercury. Dimercaprol, edetate calcium disodium, and succimer are the three agents primarily used for chelation of lead. Conclusion: Metal toxicity remains a significant public health concern. Elimination of elevated metal ions can be achieved by proper chelation agents.
    [Show full text]
  • Changes in Tissue Gadolinium Biodistribution Measured in an Animal Model Exposed to Four Chelating Agents
    Japanese Journal of Radiology (2019) 37:458–465 https://doi.org/10.1007/s11604-019-00835-1 ORIGINAL ARTICLE Changes in tissue gadolinium biodistribution measured in an animal model exposed to four chelating agents Türker Acar1,6 · Egemen Kaya2 · Mustafa Deniz Yoruk3 · Neslihan Duzenli4 · Recep Selim Senturk4 · Cenk Can4 · Lokman Ozturk3 · Canberk Tomruk5 · Yigit Uyanikgil5 · Frank J. Rybicki6 Received: 17 December 2018 / Accepted: 22 March 2019 / Published online: 30 March 2019 © Japan Radiological Society 2019 Abstract Purpose This study investigated the potential to reduce gadolinium levels in rodents after repetitive IV Gadodiamide admin- istration using several chelating agents. Materials and methods The following six groups of rats were studied. Group 1: Control; Group 2: Gadodiamide only; Group 3: Meso-2,3-Dimercaptosuccinic acid (DMSA) + Gadodiamide; Group 4: N-Acetyl-L-cysteine (NAC) + Gadodiamide; Group 5: Coriandrum sativum extract + Gadodiamide; and Group 6: Deferoxamine + Gadodiamide. Brain, kidney, and blood samples were evaluated via inductively coupled plasma mass spectrometry. The brain was also evaluated histologically. Results Kidney gadolinium levels in Groups 4 and 5 were approximately double that of Group 2 (p = 0.033 for each). There was almost no calcifcation in rat hippocampus for Group 4 rodents when compared with Groups 2, 3, 5 and 6. Conclusion Our preliminary study shows that excretion to the kidney has a higher propensity in NAC and Coriandrum sati- vum groups. It may be possible to change the distribution of gadolinium by administrating several agents. NAC may lower Gadodiamide-induced mineralization in rat hippocampus. Keywords Gadolinium deposition · Dimercaptosuccinic acid · N-Acetyl-L-cysteine · Coriandrum sativum · Deferoxamine Introduction However, the safety profle of gadolinium-based agents [1] was questioned after the discovery of nephrogenic sys- Gadolinium-based contrast agents (GBCA) have been safely temic fbrosis [2], a scleroderma-like disease characterized used in diagnostic radiology since the 1980s.
    [Show full text]
  • Recommended Chelation Protocol for Children with Blls ≥45 Μg/Dl
    The New York City Department of Health and Mental Hygiene Guidelines for Health Care Providers Recommended Chelation Protocol for Children With BLLs ≥45 μg/dL Before Providing Chelation Therapy: • Confirm the blood lead level (BLL) ≥45 μg/dL with a venous specimen processed as an emergency test unless symptoms of encephalopathy are present. • Obtain an abdominal x-ray to look for lead solid ingestion; if radio-opaque particles are found or recent ingestion is witnessed, use a cathartic. • Arrange hospitalization and chelation therapy at a facility with expertise in treating lead-poisoned children. • Provide chelation therapy in, and discharge child to, a lead-safe environment. Do not discharge until the NYC Health Department inspects the home. • Inform the NYC Health Department of the hospital admission by calling 646-632-6002. The Health Department can provide referrals to providers with expertise in treating lead intoxication and referrals to temporary lead-safe housing. Chelation Therapy For Children with Venous BLLs ≥45 μg/dL1 BLL (μg/dL) Agent, Dosage,* and Administration Special Considerations Follow-up <45 Chelation therapy not routinely recommended See Reverse for Recommended Follow-up Blood Lead Test Schedule for Children 45 to <70 • DMSA (succimer, 2,3-meso-dimercaptosuccinic acid) • Monitor for anemia, • Schedule weekly health care visits • 1050 mg DMSA / m2 / 24 hours* ÷ q8 hours PO x neutropenia, and to monitor compliance and signs of toxicity. 5 days; round dose to nearest 100 mg/day, and then hepatic toxicity. • Monitor BLLs weekly until level stabilizes, ÷ 100-mg capsules as evenly as possible for q8-hour then follow Recommended Follow-up dosing schedule.
    [Show full text]
  • Effect of Chromium(VI) on Serum Iron and Removal of Its Toxicity by Combining Deferasirox and Deferiprone Chelators in Rats
    American Journal of Pharmacology and Toxicology 8 (4): 164-169, 2013 ISSN: 1557-4962 ©2013 Science Publication doi:10.3844/ajptsp.2013.164.169 Published Online 8 (4) 2013 (http://www.thescipub.com/ajpt.toc) Effect of Chromium(VI) on Serum Iron and Removal of its Toxicity by Combining Deferasirox and Deferiprone Chelators in Rats 1S. Jamil A. Fatemi, 1Marzieh Iranmanesh and 2Faezeh Dahooee Balooch 1Department of Chemistry, Faculty of Sciences, Islamic Azad University, Kerman Branch, Kerman, Iran 2Department of Chemistry, Faculty of Sciences, Shahid Bahonar University of Kerman, Kerman, Iran Received 2013-09-26, Revised 2013-10-21; Accepted 2013-10-30 ABSTRACT The present research is aimed to characterize the potential efficiency of two chelators after chromium(VI) administration for 60 days following two doses of 15 and 30 mg kg −1 chromium(VI) per body weight daily to male rats. However, the hypothesis that the two chelators might be more efficient as combined therapy than as single therapy in removing chromium(VI) from bood serum was considered. In this way, two known chelators deferasirox and deferiprone were chosen and tested in the acute rat model. Two chelators were given orally as a single or combined therapy for a period of one week. Chromium(VI) and iron concentrations in blood were determined by flame atomic absorption spectroscopy method. Chromium is one of the most widely used industrial metals. Several million workers worldwide are estimated to be exposed to chromium compounds in an array of industries. Chromium(VI) is more readily absorbed by both inhalation and oral routes. Ingestion of large amounts of chromium(VI) can lead to severe respiratory, cardiovascular, gastrointestinal, hepatic and renal damage and potentially death.
    [Show full text]
  • Identification of a Common Chemical Signal Regulating the Induction Of
    Proc. Nati. Acad. Sci. USA Vol. 85, pp. 8261-8265, November 1988 Medical Sciences Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis (Michael acceptors/quinone reductase/glutathione S-transferase/anticarcinogens) PAUL TALALAY, MARY J. DE LONG, AND HANS J. PROCHASKA Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD 21205 Contributed by Paul Talalay, July 19, 1988 ABSTRACT Carcinogenesis is blocked by an extraordi- al inducers act are less clear (3). This paper extends our nary variety of agents belonging to many different classes- earlier efforts to identify structural features important for e.g., phenolic antioxidants, azo dyes, polycyclic aromatics, phase II enzyme induction by diphenols and phenylenedia- flavonoids, coumarins, cinnamates, indoles, isothiocyanates, mines (5). Since the specific activity of QR in the Hepa lclc7 1,2-dithiol-3-thiones, and thiocarbamates. The only known murine hepatoma cells is raised by virtually all compounds common property of these anticarcinogens is their ability to that produce coordinate elevations of phase II enzymes in elevate in animal cells the activities of enzymes that inactivate vivo (4, 5, 7), this system was used to determine the potency the reactive electrophilic forms of carcinogens. Structure- of various types of enzyme inducers. Some inducers identi- activity studies on the induction of quinone reductase fied in cell culture were also tested as inducers
    [Show full text]
  • AX Pharmaceutical Corp Product List
    AX Pharmaceutical Corp Product List A 4-Aminopyridine Acetazolamine ACTH 1-24 Acyclovir Sodium Adenosine 5 Monophosphate Adenosine 5 Tri-Phosphate Disodium Salt Albendazole Alendronate Sodium USP Alternogest Aminopentamide Sulfate Aminophylline Amlodipine Besylate Amoxicillin/Clavulanate Potassium 4:1 Amoxicillin Trihydrate Amphotericin B Ampicillin Anastrozole Aripepazole Aripiprazole Atipamezole HCl Atovaquone USP Atropine Sulfate Monohydrate Avanafil Azelastine HCl B Baclofen Benazepril HCl Betahistine Dihydrochloride Betaine Hydrochloride Betamethasone Acetate Betamethasone Dipropionate Betamethasone Sodium Phosphate Betaxolol Bexarotene Bicalutamide Bimatoprost Bisacodyl Bismuth Subcarbonate Bismuth Subsalicylate Bleomycin A5 Hydrochloride Bleomycin Sulfate Bretylium Tosylate Brimonidine Brinzolamide Bromhexine Bromocriptine Mesylate Brompheniramine Maleate Budesonide Bumetanide Bupivacaine Base Bupivacaine Hydrochloride Buprenorphine Bupropion HCl Buspirone Hydrochloride Busulfan Butaphosphan Butylated Hydroxyanisole C Cabergoline Calamine Calcium Glycerophosphate Calcium Levulinate Dihydrate Capsaicin Captopril Carbamazepine Carbazochrome Carbenoxolone Carbetocin Acetate Carbidopa Carbocisteine Carboplatin Carmustine Carprofen Carvedilol Cefadroxil Hemihydrate Cefadroxil Monohydrate Cefazolin Cefazolin Sodium Cefdinir Cefotaxime Cefotetan Disodium Cefpodoxime Cefpodoxime Proxetil Ceftazidime Ceftiofur Free Acid Ceftiofur Sodium Ceftriaxone Cefuroxime (Ceftin) Celecoxib Cephalexin Base Cephalexin Monohydrate Cesium Chloride Cetirizine
    [Show full text]
  • 514636-Unified-Chemistry.Pdf
    Qualification Accredited A LEVEL Exemplar Candidate Work CHEMISTRY A H432 For first teaching in 2015 H432/03 Summer 2017 examination series Version 1 www.ocr.org.uk/chemistry A Level Chemistry A Exemplar Candidate Work Contents Introduction 3 Question 3(b) 20 Commentary 21 Question 1(a) 4 Commentary 4 Question 3(c)(i) 22 Commentary 22 Question 1(b) 5 Commentary 5 Question 3(c)(ii) 23 Commentary 24 Question 1(c) 6 Commentary 6 Question 4(a)(i) 25 Commentary 26 Question 1(d) 7 Commentary 7 Question 4(a)(ii) 27 Commentary 28 Question 1(e) 8 Commentary 8 Question 4(b)(i) 29 Commentary 29 Question 2(a) 9 Commentary 11 Question 4(b)(ii) 30 Commentary 30 Question 2(b) 12 Commentary 12 Question 4(c)(i) 31 Commentary 31 Question 2(c) 13 Commentary 13 Question 4(c)(ii) 32 Commentary 32 Question 2(d)(i) 14 Commenary 14 Question 5(a)(i) 33 Commentary 33 Question 2(d)(ii) 15 Commentary 15 Question 5(a)(ii) 34 Commentary 34 Question 2(d)(iii) 16 Commentary 16 Question 5(a)(iii) 35 Commentary 35 Question 3(a)(i) 17 Commentary 18 Question 5(a)(iv) 36 Commentary 36 Question 3(a)(ii) 19 Commentary 19 Question 5(b) 37 Commentary 38 2 © OCR 2017 A Level Chemistry A Exemplar Candidate Work Introduction These exemplar answers have been chosen from the summer 2017 examination series. OCR is open to a wide variety of approaches and all answers are considered on their merits. These exemplars, therefore, should not be seen as the only way to answer questions but do illustrate how the mark scheme has been applied.
    [Show full text]